Biogen Inc.
Moat Score — Biogen Inc.
Total Moat Score
14 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | Biogen holds patent-protected exclusivity on its drug portfolio and deep, decades-long neuroscience R&D expertise, though several core patents (Tecfidera, and eventually newer assets) face erosion over time. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 2 / 5 | Biopharma manufacturing and R&D are not inherently low-cost; Biogen's economics depend on patent-protected pricing rather than a structural cost advantage over peers. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 3 / 5 | Patent-protected drugs allow significant pricing power during exclusivity, but this is increasingly constrained by U.S. Medicare price negotiation, payer pushback, and competition from rivals like Roche's Ocrevus in MS and Eli Lilly's Kisunla in Alzheimer's. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Biogen's drugs are sold to individual patients and prescribers; there is no mechanism by which the product becomes more valuable as more people use it. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 3 / 5 | Once patients are stabilized on a chronic therapy (particularly MS or rare-disease drugs), physicians and patients are reluctant to switch due to efficacy and safety continuity concerns, supporting durable revenue on established products. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | Biogen's core markets — multiple sclerosis and Alzheimer's — are increasingly crowded with well-capitalized competitors (Roche, Novartis, Eli Lilly), and the company is actively losing share in its legacy MS franchise. |